Genesis Healthcare Inc (GEN) Director Sells $31,907.84 in Stock

Genesis Healthcare Inc (NYSE:GEN) Director David A. Reis sold 19,456 shares of the stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $1.64, for a total value of $31,907.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

David A. Reis also recently made the following trade(s):

  • On Monday, October 29th, David A. Reis sold 7,415 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.64, for a total value of $12,160.60.
  • On Wednesday, October 10th, David A. Reis sold 3,502 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.63, for a total value of $5,708.26.
  • On Tuesday, September 4th, David A. Reis sold 47,755 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.74, for a total value of $83,093.70.
  • On Thursday, August 30th, David A. Reis sold 44,975 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.74, for a total value of $78,256.50.
  • On Tuesday, August 28th, David A. Reis sold 64,064 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.72, for a total value of $110,190.08.
  • On Friday, August 24th, David A. Reis sold 71,070 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.70, for a total value of $120,819.00.
  • On Tuesday, August 14th, David A. Reis sold 47,365 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.65, for a total value of $78,152.25.
  • On Thursday, August 9th, David A. Reis sold 101,404 shares of Genesis Healthcare stock. The stock was sold at an average price of $1.69, for a total value of $171,372.76.

Shares of NYSE GEN traded up $0.01 during mid-day trading on Monday, reaching $1.63. 2,744 shares of the company were exchanged, compared to its average volume of 229,120. The stock has a market capitalization of $261.68 million, a P/E ratio of -0.76 and a beta of 0.50. Genesis Healthcare Inc has a 1 year low of $0.60 and a 1 year high of $2.86.

Genesis Healthcare (NYSE:GEN) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the prior year, the business earned ($0.70) EPS. Analysts predict that Genesis Healthcare Inc will post -1.42 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Prescott Group Capital Management L.L.C. lifted its stake in shares of Genesis Healthcare by 6.2% during the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 624,048 shares of the company’s stock worth $1,429,000 after purchasing an additional 36,213 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Genesis Healthcare in the second quarter valued at about $120,000. California Public Employees Retirement System raised its stake in Genesis Healthcare by 23.3% in the first quarter. California Public Employees Retirement System now owns 309,910 shares of the company’s stock valued at $468,000 after buying an additional 58,610 shares during the last quarter. Macquarie Group Ltd. raised its stake in Genesis Healthcare by 27.2% in the second quarter. Macquarie Group Ltd. now owns 314,967 shares of the company’s stock valued at $721,000 after buying an additional 67,300 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Genesis Healthcare by 40.6% in the first quarter. Millennium Management LLC now owns 338,678 shares of the company’s stock valued at $511,000 after buying an additional 97,834 shares during the last quarter. Hedge funds and other institutional investors own 19.72% of the company’s stock.

A number of equities research analysts recently weighed in on GEN shares. ValuEngine cut Genesis Healthcare from a “buy” rating to a “hold” rating in a research note on Wednesday, July 18th. Cantor Fitzgerald restated a “buy” rating and set a $7.00 price objective on shares of Genesis Healthcare in a research note on Wednesday, October 3rd. Finally, Credit Suisse Group started coverage on Genesis Healthcare in a research note on Tuesday, October 16th. They set a “neutral” rating and a $1.75 price objective for the company. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $3.19.

TRADEMARK VIOLATION NOTICE: “Genesis Healthcare Inc (GEN) Director Sells $31,907.84 in Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/05/genesis-healthcare-inc-gen-director-sells-31907-84-in-stock.html.

Genesis Healthcare Company Profile

Genesis Healthcare, Inc, together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services, Rehabilitation Therapy Services, and All Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy.

See Also: Stock Symbols Definition, Examples, Lookup

Insider Buying and Selling by Quarter for Genesis Healthcare (NYSE:GEN)

Receive News & Ratings for Genesis Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genesis Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply